Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson's Disease and identifies clear opportunities to improve treatment options

Contributed by: PR Newswire

Images

PR Newswire associated1

Tags

AlpharmaximAstonStudy

More Like This

PR Newswire associated0

New research by Alpharmaxim applies behavioural science to identify and understand prescribing choices in neurogenerative diseases - and highlights the need to optimise them

Largest-ever Parkinson’s disease trial opens across UK

Patient, Research and Industry Leaders Propose Biological Definition and First Biological Staging for Parkinson's Disease

PR Newswire associated0

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson's Disease

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

PR Newswire associated0

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

PR Newswire associated0

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

Business Wire logo

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026